Printer Friendly Version View printer-friendly version
<< Back
Mediclinic Intnl plc - Director/PDMR Shareholding
RNS Number : 3423H
Mediclinic International plc
06 June 2017
 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

 

6 June 2017

 

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

Vesting of awards under the Company's Forfeitable Share Plan

 

The awards of ordinary shares in Mediclinic (the "Shares") set out in the table below, granted on 31 July 2014, vested under the Company's Forfeitable Share Plan on 31 May 2017.

 

Name

Director/ PDMR

Number of Shares vested

Number of Shares sold at ZAR 130.44 per share

Number of Shares retained1

Danie Meintjes

Director

49,423

0

49,423

Gert Hattingh

PDMR

14,734

0

14,734

Koert Pretorius

PDMR

19,806

19,806

0

David Hadley

PDMR

9,778

9,778

0

Dr Ole Wiesinger1

PDMR

17,506

0

17,506

Dr Ronnie van der Merwe

PDMR

16,507

16,507

0

 

1.     Dr Wiesinger was granted a conditional right to 17,506 Shares under the Country Schedule to the Forfeitable Share Plan on 31 July 2014. On 1 June 2017, Dr Wiesinger elected to receive the award in Shares, which he received on 5 June 2017.

 

 

The following notification made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation relates to the Company's Forfeitable Share Plan.

 

 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

Daniël Petrus Meintjes

 

2.

Reason for the notification

 

a)

Position / status

Chief Executive Officer of the Company

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Vesting of award over 49,423 ordinary shares awarded under the Company's Forfeitable Share Plan

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

Nil cost

49,423

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

49,423

 

Nil cost

 

e)

Date of the transaction

1 June 2017

 

f)

Place of the transaction

Johannesburg Stock Exchange

 

 

 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

Gert C Hattingh

 

2.

Reason for the notification

 

a)

Position / status

Chief Corporate Services Officer of the Company

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Vesting of award over 14,734 ordinary shares awarded under the Company's Forfeitable Share Plan

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

Nil cost

14,734

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

14,734

 

Nil cost

 

e)

Date of the transaction

1 June 2017

 

f)

Place of the transaction

Johannesburg Stock Exchange

 

 

 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

Koert Hendrik S Pretorius

 

2.

Reason for the notification

 

a)

Position / status

Chief Executive Officer - Mediclinic Southern Africa

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

1.  Vesting of award over 19,806 ordinary shares awarded under the Company's Forfeitable Share Plan

 

2.   Sale of 19,806 ordinary shares.

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

1.   Nil cost

1.   19,806

2.   ZAR 130.44

2.   19,806

 

d)

Aggregated information

 

Aggregated volume

 

 

Price

 

 

 

1.   19,806

2.   19,806

 

1.   Nil cost

2.   ZAR 130.44

 

e)

Date of the transaction

1 June 2017

 

f)

Place of the transaction

Johannesburg Stock Exchange

 

 

 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

David J Hadley

 

2.

Reason for the notification

 

a)

Position / status

Chief Executive Officer - Mediclinic Middle East

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

1.  Vesting of award over 9,778 ordinary shares awarded under the Company's Forfeitable Share Plan

 

2.  Sale of 9,778 ordinary shares.

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

1.   Nil cost

1.   9,778

2.   ZAR 130.44

2.   9,778

 

d)

Aggregated information

 

Aggregated volume

 

 

Price

 

 

 

1.   9,778

2.   9,778

 

1.   Nil cost

2.   ZAR 130.44

 

e)

Date of the transaction

1 June 2017

 

f)

Place of the transaction

Johannesburg Stock Exchange

 

 

 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

Dr Thorsten Ole Wiesinger

 

2.

Reason for the notification

 

a)

Position / status

Chief Executive Officer - Hirslanden

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Vesting of conditional right to 17,506 Shares under the Country Schedule to the Forfeitable Share Plan on 31 July 2014

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

Nil cost

17,506

 

d)

Aggregated information

 

Aggregated volume

 

 

Price

 

 

 

17,506

 

Nil cost

 

e)

Date of the transaction

5 June 2017

 

f)

Place of the transaction

Johannesburg Stock Exchange

 

 

 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

Dr Carel A van der Merwe

 

2.

Reason for the notification

 

a)

Position / status

Chief Clinical Officer of the Company

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

1.  Vesting of award over 16,507 ordinary shares awarded under the Company's Forfeitable Share Plan

 

2.  Sale of 16,507 ordinary shares.

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

1.   Nil cost

1.   16,507

2.   ZAR 130.44

2.   16,507

 

d)

Aggregated information

 

Aggregated volume

 

 

Price

 

 

 

1.   16,507

2.   16,507

 

1.   Nil cost

2.   ZAR 130.44

 

e)

Date of the transaction

1 June 2017

 

f)

Place of the transaction

Johannesburg Stock Exchange

 

 

 

About Mediclinic International plc

Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.

 

Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with more than 1 600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with more than 700 inpatient beds in the United Arab Emirates.

 

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

 

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.

 

For further information, please contact:

Capita Company Secretarial Services Limited

Victoria Dalby

+44 (0)207 954 9600

 

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

 

Media queries

FTI Consulting

Brett Pollard/Debbie Scott (UK)

+44 (0)20 3727 1000

Frank Ford (South Africa)

+27 (0)21 487 9000

 

Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom

Website: www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBLGDLXXGBGRL

IMPORTANT DISCLAIMER

ACCESS TO THIS AREA OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS, RULES OR REGULATIONS IN CERTAIN JURISDICTIONS. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT OR PHYSICALLY PRESENT IN SUCH A JURISDICTION), BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION ON THIS AREA OF THE WEBSITE. THESE MATERIALS ARE NOT DIRECTED AT OR TO BE ACCESSED BY, OR DISTRIBUTED OR DISSEMINATED TO, DIRECTLY OR INDIRECTLY, PERSONS RESIDENT OR PHYSICALLY LOCATED IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS, RULES OR REGULATIONS OF THAT JURISDICTION OR WOULD RESULT IN A REQUIREMENT TO COMPLY WITH CONSENT OR OTHER FORMALITY WHICH MEDICLINIC REGARDS AS UNDULY ONEROUS.

Combination of Mediclinic International Limited ("Mediclinic") and Al Noor Hospitals Group plc ("Al Noor") (the "Combination")

Access to the website

You are attempting to enter the part of the website that is designated for the publication of documents and information in connection with the Combination.

If you would like to view this part of the website, please read this notice carefully. This notice applies to all persons who view this part of the website and, depending on where you are located, may affect your rights or responsibilities. Mediclinic reserves the right to amend or update this notice at any time and you should, therefore, read it in full each time you visit the site. In addition, the contents of this part of the website may be amended at any time, in whole or in part, at the sole discretion of Mediclinic.

This part of the website contains electronic versions of materials relating to the Combination. The materials you are seeking to access are made available in good faith and for information purposes only and are subject to the terms and conditions set out below. Any person seeking to access this part of the website represents and warrants to Mediclinic that they are doing so for information purposes only.

To allow you to view information about the Combination, you must read this notice and then click "I ACCEPT". If you are unable to agree, you should click "I DECLINE" and you will not be able to view information about the Combination.

The Combination would be made by means of a scheme document to be published by Mediclinic which would contain the full terms and conditions of such Combination, including details on how it may be accepted. Any decision made in relation to the Combination should be made solely and only on the basis of the information provided in any such document.

Overseas jurisdictions

Viewing the materials you are seeking to access may be restricted under securities laws in certain jurisdictions. All persons who wish to view this part of the website must first satisfy themselves that they are not subject to any local requirements which prohibit or restrict them from doing so and should inform themselves about, and observe, any legal or regulatory requirements applicable in their jurisdiction.

These materials are not directed at or intended to be accessible by persons resident in any jurisdiction if to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.

YOU SHOULD NOT, DIRECTLY OR INDIRECTLY, DOWNLOAD, MAIL, FORWARD, DISTRIBUTE, SEND OR SHARE THE INFORMATION OR DOCUMENTS CONTAINED ON THIS PART OF THE WEBSITE TO ANY PERSON. IN PARTICULAR, YOU SHOULD NOT, DIRECTLY OR INDIRECTLY, MAIL, FORWARD, DISTRIBUTE OR SEND THE INFORMATION OR DOCUMENTS CONTAINED THEREIN TO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL TO DO SO. MEDICLINIC AND ITS ADVISERS DO NOT ASSUME ANY LIABILITY FOR ANY VIOLATION BY ANY PERSON OF ANY OF THESE RESTRICTIONS.

It is your responsibility to satisfy yourself as to the full observance of any relevant laws and regulatory requirements. If you are in any doubt, you should click on “I DECLINE” below and exit this webpage.

Cautionary Note Regarding Forward-Looking Statements

This part of the website and the information contained in it may contain certain forward-looking statements with respect to the financial condition, results of operations and businesses of Mediclinic and the Mediclinic Group (being Mediclinic and its subsidiaries and subsidiary undertakings) and Al Noor and the Al Noor Group (being Al Noor and its subsidiaries and subsidiary undertakings) following the Combination. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Mediclinic and the Mediclinic Group to market risks and statements expressing management's expectations, beliefs, estimates, forecasts, projections and assumptions, including as to future potential cost savings, synergies, earnings, cash flow and prospects. These forward-looking statements are identified by their use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "goals", "intend", "may", "objectives", "outlook", "plan", "probably", "project", "risks", "seek", "should", "target", "will" and similar terms and phrases. There are a number of factors that could affect the future operations of Mediclinic and the Mediclinic Group and Al Noor and the Al Noor Group post Combination and could cause those results to differ materially from those expressed in the forward-looking statements included in this part of the website. All forward-looking statements contained in this part of the website are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as at the specified date of the relevant document within which the statement is contained. None of Mediclinic, the Mediclinic Group, Al Noor or the Al Noor Group undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this part of the website.

Responsibility

In relation to any Combination-related materials accessible on this area of the website please note any statement of responsibility contained therein.

The documents included in this part of the website issued or published by Mediclinic speak only at the specified date of the relevant document and Mediclinic has, and accepts, no responsibility or duty to update or revise such documents.

In relation to any such announcements or other Combination-related materials issued or published by Al Noor, or which relate to Al Noor and the Al Noor Group, that are accessible on this website, the only responsibility accepted by Mediclinic and its directors is for the correctness and fairness of its reproduction.

Neither the directors of Mediclinic, nor Mediclinic, nor any of their affiliated companies, have reviewed, and no such person is or shall be responsible for or accepts any liability in respect of, any information contained on any other website which may be linked to or from this part of the website.

Other

If you are in any doubt about the contents of this part of the website or the action you should take, you should seek your own financial advice from an appropriately authorised independent financial adviser.

This notice shall be governed by and construed in accordance with English law.

CONFIRMATION OF UNDERSTANDING AND ACCEPTANCE

If you are not able to give these confirmations, you should click on “I DECLINE” below and exit the webpage.